Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
暂无分享,去创建一个
Andreas Schneeweiss | Nadia Harbeck | Christoph Thomssen | A. Schneeweiss | R. Kreienberg | A. Hinke | N. Harbeck | M. Untch | G. von Minckwitz | J. Huober | C. Jackisch | U. Nitz | C. Thomssen | W. Kuhn | G. Konecny | A. du Bois | Rolf Kreienberg | Gunter von Minckwitz | V. Moebus | Michael Untch | Jens Huober | Andreas du Bois | I. Runnebaum | Walther Kuhn | H. Lueck | Christian Jackisch | Gottfried E Konecny | Christian Kurbacher | Ingo B Runnebaum | Volker Moebus | Ulrike Nitz | Hans-Joachim Lueck | Axel Hinke | C. Kurbacher
[1] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[2] H. Earl,et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. , 2006, The New England journal of medicine.
[3] D. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. , 2006, JAMA.
[4] Robert B Livingston,et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.
[5] P. Bruzzi,et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. , 2005, Journal of the National Cancer Institute.
[6] W. Gradishar. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings From NCIC CTG MA.17 , 2006 .
[7] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Bergh,et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.
[10] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Hudis,et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Schraub,et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Larry Norton,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.
[14] D. Tu,et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Kreienberg,et al. Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] V. Noronha,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[17] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Schneeweiss,et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) , 2007 .
[19] Xueri Li,et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .
[20] Dongsheng Tu,et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Gelber,et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.
[23] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[24] J. Ledermann,et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] O. Dizdar,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[26] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[27] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .